Menlo's serlopitant misses in Phase II for pruritus associated with atopic dermatitis

Menlo Therapeutics Inc. (NASDAQ:MNLO) said serlopitant (VPD-737) missed the primary and key secondary endpoints in the U.S. Phase II ATOMIK (MTI-103) trial to treat pruritus associated with atopic dermatitis.

ATOMIK enrolled 484 atopic dermatitis patients ages 13 and older with a weekly worst-itch numeric rating scale (WI-NRS) score of at least 6 points during the two-week screening period. On ATOMIK's primary endpoint, once-daily oral serlopitant led to reductions in WI-NRS score from baseline to week six of 2.32 points at the 1 mg dose and of 2.25 points at the 5 mg dose compared with 2.01 points for placebo (p=0.11 and p=0.17, respectively)...